Mechanism of neutrophil dysfunction: Neutrophil serine proteases cleave and inactivate the C5a receptor

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1787-1795

  Van Den Berg, Carmen W ^a   Tambourgi, Denise V ^b   Clark, Howard W ^c   Hoong, S Julie ^a   Spiller, O Brad ^a   McGreal, Eamon P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTO BUTANTAN   (Brazil)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHOALVEOLAR LAVAGE FLUID; CATHEPSIN G; CELL LINE; CHILD; COMPLEMENT ACTIVATION; HUMANS; LEUKOCYTE ELASTASE; MYELOBLASTIN; NEUTROPHIL ACTIVATION; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; SERINE PROTEASES; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 84894239912     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301920     Document Type: Article

References (44)

1. Döring, G. 1994. The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. Care Med. 150: S114-S117.
2. Voynow, J. A., B. M. Fischer, and S. Zheng. 2008. Proteases and cystic fibrosis. Int. J. Biochem. Cell Biol. 40: 1238-1245.
3. Griese, M., M. Kappler, A. Gaggar, and D. Hartl. 2008. Inhibition of airway proteases in cystic fibrosis lung disease. Eur. Respir. J. 32: 783-795.
4. Hartl, D., P. Latzin, P. Hordijk, V. Marcos, C. Rudolph, M. Woischnik, S. Krauss-Etschmann, B. Koller, D. Reinhardt, A. A. Roscher, et al. 2007. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat. Med. 13: 1423-1430.
5. McGreal, E. P., P. L. Davies, W. Powell, S. Rose-John, O. B. Spiller, I. Doull, S. A. Jones, and S. Kotecha. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochim. Biophys. Acta 1802: 649-658.
6. Berger, M., R. U. Sorensen, M. F. Tosi, D. G. Dearborn, and G. Döring. 1989. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J. Clin. Invest. 84: 1302-1313.
7. Tosi, M. F., H. Zakem, and M. Berger. 1990. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J. Clin. Invest. 86: 300-308.
8. Liau, D. F., N. X. Yin, J. Huang, and S. F. Ryan. 1996. Effects of human polymorphonuclear leukocyte elastase upon surfactant proteins in vitro. Biochim. Biophys. Acta 1302: 117-128.
9. Duvoix, A., R. M. Mackay, N. Henderson, E. McGreal, A. Postle, K. Reid, and H. Clark. 2011. Physiological concentration of calcium inhibits elastase-induced cleavage of a functional recombinant fragment of surfactant protein D. Immunobiology 216: 72-79.
10. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
11. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
12. Monk, P. N., A. M. Scola, P. Madala, and D. P. Fairlie. 2007. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152: 429-448.
13. Larsen, G. L., B. C. Mitchell, T. B. Harper, and P. M. Henson. 1982. The pulmonary response of C5 sufficient and deficient mice to Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 126: 306-311.
14. Cerquetti, M. C., D. O. Sordelli, J. A. Bellanti, and A. M. Hooke. 1986. Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds. Infect. Immun. 52: 853-857.
15. Höpken, U. E., B. Lu, N. P. Gerard, and C. Gerard. 1996. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383: 86-89.
16. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
17. Seely, A. J., J. F. Naud, G. Campisi, B. Giannias, S. Liu, A. DiCarlo, L. E. Ferri, J. L. Pascual, J. Tchervenkov, and N. V. Christou. 2002. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. Ann. Surg. 235: 550-559.
18. Huber-Lang, M. S., N. C. Riedeman, J. V. Sarma, E. M. Younkin, S. R. McGuire, I. J. Laudes, K. T. Lu, R. F. Guo, T. A. Neff, V. A. Padgaonkar, et al. 2002. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 16: 1567-1574.
19. Guo, R. F., N. C. Riedemann, K. D. Bernacki, V. J. Sarma, I. J. Laudes, J. S. Reuben, E. M. Younkin, T. A. Neff, J. D. Paulauskis, F. S. Zetoune, and P. A. Ward. 2003. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J. 17: 1889-1891.
20. Conway Morris, A., K. Kefala, T. S. Wilkinson, K. Dhaliwal, L. Farrell, T. Walsh, S. J. Mackenzie, H. Reid, D. J. Davidson, C. Haslett, et al. 2009. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am. J. Respir. Crit. Care Med. 180: 19-28.
21. Unnewehr, H., D. Rittirsch, J. V. Sarma, F. Zetoune, M. A. Flierl, M. Perl, S. Denk, M. Weiss, M. E. Schneider, P. N. Monk, et al. 2013. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J. Immunol. 190: 4215-4225.
22. van den Berg, C. W., R. M. Gonçalves-de-Andrade, C. K. Okamoto, and D. V. Tambourgi. 2012. C5a receptor is cleaved by metalloproteases induced by sphingomyelinase D from Loxosceles spider venom. Immunobiology 217: 935-941.
23. Jagels, M. A., J. A. Ember, J. Travis, J. Potempa, R. Pike, and T. E. Hugli. 1996. Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis: cleavage of leukocyte C5a receptor. Adv. Exp. Med. Biol. 389: 155-164.
24. Siciliano, S. J., T. E. Rollins, J. DeMartino, Z. Konteatis, L. Malkowitz, G. Van Riper, S. Bondy, H. Rosen, and M. S. Springer. 1994. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 91: 1214-1218.
25. Tralau, T., U. Meyer-Hoffert, J. M. Schröder, and O. Wiedow. 2004. Human leukocyte elastase and cathepsin G are specific inhibitors of C5a-dependent neutrophil enzyme release and chemotaxis. Exp. Dermatol. 13: 316-325.
26. Al-Mohanna, F. A., and M. B. Hallett. 1988. The use of fura-2 to determine the relationship between cytoplasmic free Ca2+ and oxidase activation in rat neutrophils. Cell Calcium 9: 17-26.
27. Witko-Sarsat, V., L. Halbwachs-Mecarelli, A. Schuster, P. Nusbaum, I. Ueki, S. Canteloup, G. Lenoir, B. Descamps-Latscha, and J. A. Nadel. 1999. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am. J. Respir. Cell Mol. Biol. 20: 729-736.
28. Rubio, F., J. Cooley, F. J. Accurso, and E. Remold-O'Donnell. 2004. Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease. Thorax 59: 318-323.
29. DeMartino, J. A., G. Van Riper, S. J. Siciliano, C. J. Molineaux, Z. D. Konteatis, H. Rosen, and M. S. Springer. 1994. The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J. Biol. Chem. 269: 14446-14450.
30. Higginbottom, A., S. A. Cain, T. M. Woodruff, L. M. Proctor, P. K. Madala, J. D. Tyndall, S. M. Taylor, D. P. Fairlie, and P. N. Monk. 2005. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J. Biol. Chem. 280: 17831-17840.
31. Buck, E., H. Bourne, and J. A. Wells. 2005. Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor. J. Biol. Chem. 280: 4009-4012.
32. Furebring, M., L. Håkansson, P. Venge, and J. Sjölin. 2006. C5a, interleukin-8 and tumour necrosis factor-alpha-induced changes in granulocyte and monocyte expression of complement receptors in whole blood and on isolated leukocytes. Scand. J. Immunol. 63: 208-216.
33. Ali, H., R. M. Richardson, E. D. Tomhave, J. R. Didsbury, and R. Snyderman. 1993. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlate with differences in desensitization. J. Biol. Chem. 268: 24247-24254.
34. Bender, J. G., D. E. Van Epps, and D. E. Chenoweth. 1987. Independent regulation of human neutrophil chemotactic receptors after activation. J. Immunol. 139: 3028-3033.
35. Goldstein, I. M., and G. Weissmann. 1974. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113: 1583-1588.
36. Binder, R., A. Kress, and M. Kirschfink. 1999. Modulation of C5a-mediated effector functions of human polymorphonuclear leukocytes by tumor necrosis factor alpha and granulocyte macrophage colony-stimulating factor. Exp. Clin. Immunogenet. 16: 212-225.
37. Tomhave, E. D., R. M. Richardson, J. R. Didsbury, L. Menard, R. Snyderman, and H. Ali. 1994. Cross-desensitization of receptors for peptide chemoattractants. Characterization of a new form of leukocyte regulation. J. Immunol. 153: 3267-3275.
38. Cottrell, G. S. 2013. Roles of proteolysis in regulation of GPCR function. Br. J. Pharmacol. 168: 576-590.
39. Van Epps, D. E., S. Simpson, J. G. Bender, and D. E. Chenoweth. 1990. Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J. Immunol. 144: 1062-1068.
40. Van Epps, D. E., S. J. Simpson, and D. E. Chenoweth. 1992. C5a and formyl peptide receptor regulation on human monocytes. J. Leukoc. Biol. 51: 393-399.
41. Naik, N., E. Giannini, L. Brouchon, and F. Boulay. 1997. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell Sci. 110: 2381-2390.
42. Suvorova, E. S., J. M. Gripentrog, and H. M. Miettinen. 2005. Different endocytosis pathways of the C5a receptor and the N-formyl peptide receptor. Traffic 6: 100-115.
43. Pease, J. E., and M. D. Barker. 1993. N-linked glycosylation of the C5a receptor. Biochem. Mol. Biol. Int. 31: 719-726.
44. Vandivier, R. W., P. M. Henson, and I. S. Douglas. 2006. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129: 1673-1682.